MedTrace Logo

Nitroglycerin Prevents Radial Artery Occlusion

NCT02105493 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1706

Last updated 2014-04-07

No results posted yet for this study

Summary

Trans-radial approach (TRA) has becoming popular and widely adopted over the last decade. However, radial artery occlusion (RAO) continues to be one of the limitation of trans-radial access and potentially limits the radial artery as an access site in the future. Several strategies have been used to decrease the incidence of RAO including the use of anticoagulation, maintenance of patency during hemostasis, or shortening the duration of compression. Currently, there is no data whether vasoactive pharmacological therapy such as nitroglycerin administered intra-arterially at the end of the procedure may reduce the incidence of RAO. It is hypothesized that the addition of nitroglycerin (nitric oxide donor) at the end of a TRA procedure may reduce the incidence of RAO.

Conditions

  • Injury of Radial Artery

Interventions

DRUG

500 microgram of Nitroglycerin

500 microgram of Nitroglycerin (in 5 mL saline) given intra-arterially through the sheath at the end of transradial procedure

DRUG

Saline 5 mL

Saline 5 mL given intra-arterially through the sheath at the end of transradial procedure

Sponsors & Collaborators

  • National Cardiovascular Center Harapan Kita Hospital Indonesia

    lead OTHER

Principal Investigators

  • Surya Dharma, MD, PhD · National Cardiovascular Center Harapan Kita

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-02-28
Completion
2014-03-31

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02105493 on ClinicalTrials.gov